Esofag-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD) and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), selectively inhibits the H+/K+ ATPase enzyme system in gastric parietal cells, leading to a significant reduction in gastric acid secretion. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance by reducing dosing frequency. Esofag-D is indicated for the treatment of erosive esophagitis, symptomatic GERD, and prevention of acid-related damage to the esophageal mucosa. It may also be utilized in the management of Zollinger-Ellison syndrome and other hypersecretory conditions. The combination therapy addresses both acid suppression and motility enhancement, offering comprehensive symptom relief. Caution is advised in patients with cardiac arrhythmias, liver impairment, or concurrent use of QT-prolonging agents. Administration should follow medical guidance, considering potential drug interactions and contraindications. Overall, Esofag-D Capsule SR provides an effective therapeutic option for patients requiring combined acid suppression and prokinetic treatment.